Who
Christopher Nathan Martin
Director
Company insider
Files Form 4 as: Director, Achieve Life Sciences; Director, Edgewise Therapeutics; Director, Oruka Therapeutics.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 19 Nov 2025
- Last trade
- 27 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,136 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,136 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —47,250 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —47,250 at $0.00 | filing |
| 11 Dec 2025filed 11 Dec 2025 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 19 Nov 2025filed 24 Nov 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,150 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.